Interpretation of the anti-cancer action mechanism and molecular targets of Thiotepa

Thiotepa (Thiotepa) is a classic alkylating agent anti-tumor drug that is widely used in the treatment of a variety of malignant tumors, including breast cancer, ovarian cancer, bladder cancer and pretreatment before bone marrow transplantation. Its anti-cancer effect mainly comes from its potent DNAalkylation ability, which can interfere with the DNA structure and function of tumor cells, thereby inhibiting cell division and inducing apoptosis of tumor cells.

At the molecular level, thiotepa is a triethyleneimine derivative, which can be metabolized into the active intermediate TEPA (triethylenephosphoramide) in the body. These active substances covalently bind to DNA bases (especially guanine), forming DNA intermittent or DNA intra-chain cross-links, thereby preventing DNA replication and transcription. This mechanism of action is particularly effective for tumor cells in the active proliferation phase of the cell cycle and has broad-spectrum anti-tumor activity.

Unlike modern targeted drugs, thiotepa does not act on a single molecular target, but achieves cytotoxicity through non-specific DNA damage. Although this mechanism lacks precision, it still has important therapeutic value in certain highly proliferative tumors (such as certain brain tumors, leukemias, or malignant lymphomas). In the pretreatment regimen for bone marrow transplantation, thiotepa is often used in combination with other drugs to eliminate residual tumor cells in the body and suppress immune responses.

In general, the anti-cancer mechanism of thiotepa is centered on DNA cross-linking and cytotoxicity, and is suitable for clinical scenarios that require strong removal of tumor burden. Although its non-targeting nature may bring certain toxic side effects, it still has an irreplaceable clinical position in the treatment of multiple, relapsed or refractory tumors. With the development of new generation chemotherapy and immune combination strategies, thiotepa is gradually being integrated into more personalized treatment plans.

Reference materials:https://www.drugs.com/